Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Diabetes and Osteoporosis Are Related: Prof. Okazaki
August 10, 2009
- Industry Must Give Clearer Explanations about Need for NHI Pricing System Reform: Mr Kinoshita
August 10, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 10, 2009
- Marketing Authorization Holders Must Maintain Close Communication with Suppliers
August 10, 2009
- Hisamitsu to Increase Overseas Sales to 15% of Total Sales
August 10, 2009
- OMT Creates First Targeted Immunoglobulin Knockout Rats
August 10, 2009
- Takeda to Promote Wyeths Seltouch from October
August 10, 2009
- Comprehensive Clinical Trial Program Proposed in NDAs for Oral Antidiabetics
August 10, 2009
- Daiichi Sankyo to Launch Effient in the US in August
August 10, 2009
- REGULATORY NEWS IN BRIEF
August 10, 2009
- Zeria to Acquire Tillotts
August 10, 2009
- Introduce Financial Incentives to Promote Use of Generics: Mr Sawai of JGA
August 10, 2009
- Erbitux Sales to Exceed 1 Bil. Euro Mark
August 10, 2009
- Combination Drugs Interfere with Promotion of Generics: JSHP
August 10, 2009
- No. 3 and No. 4 CSOs to Merge
August 10, 2009
- Establish Regional Networks to Promote Use of Generics: Mr Kinoshita
August 10, 2009
- BUSINESS NEWS IN BRIEF
August 10, 2009
- 8 Prefectures to Prepare Lists of Generics Stocked by Regional Pharmacies
August 10, 2009
- Eisai Licenses Drug-Eluting Bead Products from Biocompatibles
August 10, 2009
- JPMA to Propose Fee-for-Service for Clinical Trials
August 10, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…